Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Emil Kakkis Insider Profile
4 Followers
Emil Kakkis, President & CEO, Director at Ultragenyx Pharmaceutical, holds 2.79M shares in Ultragenyx Pharmaceutical (Ticker: RARE), holds 44.27K shares in BioMarin Pharmaceutical (Ticker: BMRN). Most recently, Emil Kakkis Sold ― shares of Ultragenyx Pharmaceutical on Sep 05, 2024 for an estimated value of 1.12M.
Emil Kakkis Ultragenyx Pharmaceutical (RARE)President & CEO, Director
Ultragenyx Pharmaceutical (RARE)
President & CEO, Director
Ranked #3,193 out of 99,335 Corporate Insiders
Profitable Transactions
5 out of 7 Profitable Transactions
Average Return
+60.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Emil Kakkis holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Mar 13, 2020 - Mar 13, 2021
Return:+192.90%
The most profitable trade made by Emil Kakkis
Emil Kakkis's Trading History
Ultragenyx Pharmaceutical
Sep 05, 2024
President & CEO, Director
Informative Sell
1.12M
$128.33M
BioMarin Pharmaceutical
Mar 04, 2009
CMO
Uninformative Sell
92.39K
$2.81M
List of latest transactions for each holding click on a transaction to see Emil Kakkis's performance on stock
You May Also Like
Emil Kakkis insider profile FAQ
What is the percentage of profitable transactions made by Emil Kakkis?
The percentage of profitable transactions made by Emil Kakkis is 71%.
What is the average return per transaction made by Emil Kakkis?
The average return per transaction made by Emil Kakkis is 60.60%.
What stocks does Emil Kakkis hold?
Emil Kakkis holds: RARE, BMRN stocks.
What was Emil Kakkis’s latest transaction?
Emil Kakkis latest transaction was an Informative Sell of $1.12M.
What was Emil Kakkis's most profitable transaction?
Emil Kakkis’s most profitable transaction was an Informative Buy of RARE stock on March 13, 2020. The return on the trade was 192.90%.
What is Emil Kakkis's role in Ultragenyx Pharmaceutical?
Emil Kakkis's role in Ultragenyx Pharmaceutical is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.